Effect of acute ghrelin administration on glycaemia and insulin levels in obese patients

What Was Tested

Researchers studied Ghrelin and GHRH (Growth Hormone-Releasing Hormone) in this randomized controlled trial publication.

Ghrelin is a 28-amino-acid peptide, predominantly produced by the stomach.

However, the pancreatic endocrine response to ghrelin in obesity is unclear at present.

The aim of this study was to clarify whether ghrelin administration influences glucose and insulin levels in obese patients.

Who Took Part

By PubMed's age tags, the people studied were adults, women only.

How the Study Was Run

In design terms this was a randomized and placebo-controlled study.

Because people in this Ghrelin study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

A placebo (an inactive look-alike) gave the Ghrelin group a baseline to be compared against.

Blood samples were taken at appropriate intervals for determination of glucose and insulin.

Statistical analyses were performed by Wilcoxon and Mann-Whitney tests.

What Was Measured

The subject headings attached to it are Blood Glucose, Drug Combinations, Ghrelin, Growth Hormone-Releasing Hormone, Insulin, Obesity and Peptide Hormones.

What This Means in Plain Language

The paper is a randomized and placebo-controlled study of Ghrelin and GHRH (Growth Hormone-Releasing Hormone).

The abstract goes on to report its results in about 7 sentences; this page does not restate them, so read the paper for the findings and their limits.

The publication is from 2006 (Diabetes, obesity & metabolism), a journal based in England.

More context: the Ghrelin compound page and the GHRH (Growth Hormone-Releasing Hormone) compound page, all human trials.